retatrutide mechanism Research Guide: What the Phase 2 Trial Data Reported (2026) retatrutide mechanism triple agonist glp-1

In 2022, the FDA added both semaglutide and tirzepatide to its drug-shortage list

It is a pharmacological consequence of pharmacokinetics

The growth is attributed to its strong clinical performance, precise targeting, and long half-life properties

They gradually shift the signaling pathways in your brain and gut until, one day, you realize that the constant background noise of hunger has gone quiet

Dual-barb microneedle with JAK/STAT inhibitor-loaded nanovesicles encapsulation for tendinopathy

This blog covers a recent Renegade Research Roundtable, two studies reporting on the effects of GLP-1 agonists on people with mast cell activation syndrome (MCAS) and intracranial hypertension, and two major GLP-1 long-COVID trials getting underway